Trial Outcomes & Findings for Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation (NCT NCT04339101)
NCT ID: NCT04339101
Last Updated: 2025-03-24
Results Overview
GRFS is defined as time from the date of transplantation to the first time of observing following events: grade 3-4 acute graft versus host disease (GVHD), chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first. Kaplan-Meier curve will be generated for GRFS.
Recruitment status
ACTIVE_NOT_RECRUITING
Study phase
PHASE2
Target enrollment
59 participants
Primary outcome timeframe
From the date of transplantation to the first time of observing following events: grade 3-4 acute graft versus host disease (GVHD), chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first, assessed at 1 year post transplant.
Results posted on
2025-03-24
Participant Flow
Participant milestones
| Measure |
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity.
Fludarabine: Given via infusion
Itacitinib Adipate: Given PO
Melphalan: Given IV
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Sirolimus: Given PO
Tacrolimus: Given IV or PO
|
|---|---|
|
Overall Study
STARTED
|
59
|
|
Overall Study
COMPLETED
|
59
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
Baseline characteristics by cohort
| Measure |
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
n=59 Participants
RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity.
Fludarabine: Given via infusion
Itacitinib Adipate: Given PO
Melphalan: Given IV
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Sirolimus: Given PO
Tacrolimus: Given IV or PO
|
|---|---|
|
Age, Continuous
|
63 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
23 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
36 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
10 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
48 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
59 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: From the date of transplantation to the first time of observing following events: grade 3-4 acute graft versus host disease (GVHD), chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first, assessed at 1 year post transplant.GRFS is defined as time from the date of transplantation to the first time of observing following events: grade 3-4 acute graft versus host disease (GVHD), chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first. Kaplan-Meier curve will be generated for GRFS.
Outcome measures
| Measure |
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
n=59 Participants
RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity.
Fludarabine: Given via infusion
Itacitinib Adipate: Given PO
Melphalan: Given IV
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Sirolimus: Given PO
Tacrolimus: Given IV or PO
|
|---|---|
|
Graft-versus-host Disease Free Relapse Free (GRFS) at 1 Year
|
56 percentage of probability
Interval 41.0 to 69.0
|
SECONDARY outcome
Timeframe: From day 0 (date of stem cell infusion) through 100 days post-transplantAcute GVHD will be graded and staged according to the Consensus Grading.
Outcome measures
| Measure |
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
n=59 Participants
RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity.
Fludarabine: Given via infusion
Itacitinib Adipate: Given PO
Melphalan: Given IV
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Sirolimus: Given PO
Tacrolimus: Given IV or PO
|
|---|---|
|
Cumulative Incidence of Grade II-IV Acute GVHD
|
4 percentage of probability
Interval 1.0 to 13.0
|
SECONDARY outcome
Timeframe: From the date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, whichever occurs first, assessed at 1 year post transplantKaplan-Meier curve will be generated for PFS.
Outcome measures
| Measure |
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
n=59 Participants
RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity.
Fludarabine: Given via infusion
Itacitinib Adipate: Given PO
Melphalan: Given IV
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Sirolimus: Given PO
Tacrolimus: Given IV or PO
|
|---|---|
|
Progression Free Survival (PFS)
|
70 percentage of probability
Interval 54.0 to 81.0
|
Adverse Events
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
Serious events: 9 serious events
Other events: 59 other events
Deaths: 14 deaths
Serious adverse events
| Measure |
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
n=59 participants at risk
RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity.
Fludarabine: Given via infusion
Itacitinib Adipate: Given PO
Melphalan: Given IV
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Sirolimus: Given PO
Tacrolimus: Given IV or PO
|
|---|---|
|
Blood and lymphatic system disorders
E. Faecalis Bactermia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
GI Bleed
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
polymicrobial pneumonia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Cardiac disorders
Cardiac Failure
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Intermittent
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
GI Bleed
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Disease progression
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Tractable nausea and Vomiting
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Bacteremia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Sepsis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Bordetella Parapertussis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
3.4%
2/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
Other adverse events
| Measure |
Treatment (Itacitinib Adipate, Tacrolimus, Sirolimus)
n=59 participants at risk
RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity.
Fludarabine: Given via infusion
Itacitinib Adipate: Given PO
Melphalan: Given IV
Quality-of-Life Assessment: Ancillary studies
Questionnaire Administration: Ancillary studies
Sirolimus: Given PO
Tacrolimus: Given IV or PO
|
|---|---|
|
General disorders
skin tear buttock
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
sore on lip
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
sore throat
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
strep viridians ( port culture)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
subconjunctival hemorrhage left eye
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
submandibular tenderness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
swelling lower extremities
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
throat pain
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
General disorders
trans aminasitis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
tremors bilateral upper extremities
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
upper extremity Pruritis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
venoclussive disease
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
xerostomia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Hepatobiliary disorders
Portal hypertension
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Infections and infestations
BK cystitis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Bacteremia
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Infections and infestations
Catheter related infection
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Cytomegalovirus infection reactivation
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Infections and infestations
Enterocolitis infectious
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Infections and infestations
Papulopustular rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Pharyngitis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Sepsis
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Infections and infestations
Sinusitis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Skin infection
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Thrush
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
Upper respiratory infection
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
bk viremia positive
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
hickman infection
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Infections and infestations
strepiviridans
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Injury, poisoning and procedural complications
Bruising
|
13.6%
8/59 • Number of events 11 • Up to 2 years post transplant.
|
|
Injury, poisoning and procedural complications
Fall
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Injury, poisoning and procedural complications
Fracture
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Investigations
Alanine aminotransferase increased
|
40.7%
24/59 • Number of events 26 • Up to 2 years post transplant.
|
|
Investigations
Alkaline phosphatase increased
|
20.3%
12/59 • Number of events 13 • Up to 2 years post transplant.
|
|
Investigations
Aspartate aminotransferase increased
|
42.4%
25/59 • Number of events 27 • Up to 2 years post transplant.
|
|
Investigations
Blood bilirubin increased
|
18.6%
11/59 • Number of events 13 • Up to 2 years post transplant.
|
|
Investigations
Blood lactate dehydrogenase increased
|
59.3%
35/59 • Number of events 38 • Up to 2 years post transplant.
|
|
Investigations
CD4 lymphocytes decreased
|
1.7%
1/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Investigations
Cardiac troponin I increased
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Investigations
Cholesterol high
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Investigations
Creatinine increased
|
45.8%
27/59 • Number of events 28 • Up to 2 years post transplant.
|
|
Investigations
Haptoglobin decreased
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Investigations
Lymphocyte count decreased
|
81.4%
48/59 • Number of events 64 • Up to 2 years post transplant.
|
|
Investigations
Neutrophil count decreased
|
81.4%
48/59 • Number of events 58 • Up to 2 years post transplant.
|
|
Investigations
Platelet count decreased
|
93.2%
55/59 • Number of events 65 • Up to 2 years post transplant.
|
|
Investigations
Urine output decreased
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Investigations
Weight gain
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Investigations
Weight loss
|
8.5%
5/59 • Number of events 5 • Up to 2 years post transplant.
|
|
Investigations
White blood cell decreased
|
86.4%
51/59 • Number of events 66 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Anorexia
|
49.2%
29/59 • Number of events 29 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Dehydration
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
72.9%
43/59 • Number of events 50 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
5.1%
3/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hyperlipidemia
|
5.1%
3/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypernatremia
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hyperphosphatemia
|
25.4%
15/59 • Number of events 15 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypertriglyceridemia
|
76.3%
45/59 • Number of events 46 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
78.0%
46/59 • Number of events 47 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
78.0%
46/59 • Number of events 51 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
72.9%
43/59 • Number of events 45 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
86.4%
51/59 • Number of events 58 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
71.2%
42/59 • Number of events 52 • Up to 2 years post transplant.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
59.3%
35/59 • Number of events 35 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Ankle pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
non anion gap metabolic acidosis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
nonocclusive DVT rigiht axillary and basilic veins
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
occult blood in stool
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
pain at port site
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
pain left forearm
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
pain right flank
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
petechiae bilateral arms
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
pruritic Rash Scalp
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
pruritic rash back
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
pruritic rash face
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
rare candida albicans (on BAL)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
rectal irritation
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
redness bilateral arms
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
respiratory Adenovirus (asymptomatic)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right ankle pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right ankle swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right hand open wound
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right leg cramping
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right pleural effusion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right posterior thigh pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right sided oral gum swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
right upper lip ulceration
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
scalp discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
scattered rales on bilateral peripheral lungs
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
scrotal skin darkening
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
shivers
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
shortness of breath
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
shoulder bruising
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
shoulder pain
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
16.9%
10/59 • Number of events 10 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
28.8%
17/59 • Number of events 17 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
11.9%
7/59 • Number of events 7 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
13.6%
8/59 • Number of events 8 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Hoarseness
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
10.2%
6/59 • Number of events 6 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
10.2%
6/59 • Number of events 6 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Pnemonia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Postnasal drip
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhea
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
20.3%
12/59 • Number of events 12 • Up to 2 years post transplant.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Lip
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Back Rash
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Chest Rash
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis under left eye
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Erhyematous Patches on Back
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Erythematous Patches bilateral arms
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Erythematous patches bilateral legs
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Facial Rash
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Facial rash
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
ITCHING
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Left upper back petechial rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Macular Rash Back
|
1.7%
1/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Papular Chest Rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Pustular Lesion Right side of nose
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Pustular lesion right side of chin
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Rash
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Rash Bilateral Thighs
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Rash Chest
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
16.9%
10/59 • Number of events 11 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Rash upper Extremities
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Skin erythema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
Skin lesion (L) inner cheek
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
irritation near seton
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
itching
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Skin and subcutaneous tissue disorders
red spots on hand
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Vascular disorders
Flushing
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Vascular disorders
Hematoma
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Vascular disorders
Hypertension
|
47.5%
28/59 • Number of events 29 • Up to 2 years post transplant.
|
|
Vascular disorders
Hypotension
|
15.3%
9/59 • Number of events 9 • Up to 2 years post transplant.
|
|
Vascular disorders
Thromboembolic event
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
42.4%
25/59 • Number of events 26 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
11.9%
7/59 • Number of events 7 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Generalized bone pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
18.6%
11/59 • Number of events 12 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Generalized musculoskeletal pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Joint pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Muscle cramp
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain in Knee
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
11.9%
7/59 • Number of events 7 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
11.9%
7/59 • Number of events 9 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
Worsening muscle/back pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Musculoskeletal and connective tissue disorders
lower back pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal Inclusion Cysts
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Nervous system disorders
Aphonia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Nervous system disorders
Dizziness
|
18.6%
11/59 • Number of events 11 • Up to 2 years post transplant.
|
|
Nervous system disorders
Dysgeusia
|
25.4%
15/59 • Number of events 15 • Up to 2 years post transplant.
|
|
Nervous system disorders
Headache
|
67.8%
40/59 • Number of events 44 • Up to 2 years post transplant.
|
|
Nervous system disorders
Paresthesia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Nervous system disorders
Seizure
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Nervous system disorders
Somnolence
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Nervous system disorders
Tremor
|
16.9%
10/59 • Number of events 11 • Up to 2 years post transplant.
|
|
Psychiatric disorders
Agitation
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Psychiatric disorders
Anxiety
|
20.3%
12/59 • Number of events 12 • Up to 2 years post transplant.
|
|
Psychiatric disorders
Confusion
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Psychiatric disorders
Delirium
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Psychiatric disorders
Depression
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Psychiatric disorders
Hallucinations
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Psychiatric disorders
Insomnia
|
44.1%
26/59 • Number of events 26 • Up to 2 years post transplant.
|
|
Psychiatric disorders
disorientation
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Psychiatric disorders
word finding difficulties
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Acute kidney injury
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Bladder spasm
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Burning while urninating
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Dysuria
|
16.9%
10/59 • Number of events 10 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Hematuria
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Proteinuria
|
8.5%
5/59 • Number of events 5 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Urinary frequency
|
20.3%
12/59 • Number of events 13 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Urinary incontinence
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Urinary retention
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
Urinary urgency
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Renal and urinary disorders
urinary hesitancy
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Reproductive system and breast disorders
Testicular pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Reproductive system and breast disorders
Vaginal pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
multifocal pneumonia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
neck discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
neck tightness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
night sweats
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Rash around Edges of PICC line dressing
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Rectal Discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Relapsed AML
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Rhinitis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right Arm Swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right Flank Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right Lower Lip Swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right Sided Abdominal pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right Sided Chest Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right Sided Jaw Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right Testicle Edema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right lower lip lesions
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right shoulder Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Right upper extremity Swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Rosacea
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Sciatica pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Septic Shock
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Shoulder pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Sore gums
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Spasm and tingling of right hand
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Stomach pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Stress incontinence
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Throat pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Tinnitus left ear
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Toe pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Tongue Lesions
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Tongue Swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Transaminitis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Upper Extremity Rash
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Upper Extremity Rash * non pruritic*
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Upper GI discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Urinary Burning
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Urinary Hesitancy
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Vaginal Pruritus
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Vision Changes
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Vitamin D Deficiency
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Vitamin D Insufficiency
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Xerosis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
abdominal cramping
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
abdominal rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
abdominal tenderness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
abdomincal discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
acid reflux
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
acute febrile illness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
acute gvhd of skin <25%
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
acute liver gvhd
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
acute on chronic hyponatremia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
acute renal failure
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
agvhd of skin
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
anal discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
anion gap acidosis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
ankle pain
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
back pruritis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
back rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
backache
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bilateral ankle edema
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
bilateral arm bone pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bilateral leg fatigue
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bilateral leg pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bilateral lower extremity pain
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
bilateral lower leg pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bilateral pleural effusion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bilateral posterior shoulder blade pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bilateral subdural hematoma
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
black tongue discoloration
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
blood blister right upper buccal mucosa
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bloody mucous plug right upper lung
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bone hip pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
bottom lip pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
cervical adenopathy
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
chest rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
dry cough
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
ecchymosis right arm
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
edema bilateral lower extremities
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
epigastric discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
epigastric pain
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
erythematous rash face
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
esophageal NG Tube Trauma
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
facial edema
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
facial redness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
follicular rash neck
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
foot pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
forehead dryness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
forgetfulness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hand Tremors
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
heart murmur
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
heartburn
|
8.5%
5/59 • Number of events 5 • Up to 2 years post transplant.
|
|
General disorders
hematochezia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hernia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hickman Access Complication
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hip pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hospital acquired pressure injury to back of neck and sacrum
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hot sensation while urinating
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hypersensitivity right upper chest
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
hypogammaglobulinemia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
indigestion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
jaw Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
knee effusion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
knee pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left Upper extremity Swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left ear lesion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left eye conjuntiva redness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left eyelid dryness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left lower eye lid redness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left lower eyelid itchiness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left rib pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left sided pleuritic chest pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left toe gout
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left wrist swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
leg bruising
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
leg discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
lesion left lower lip
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
lower back pain
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
General disorders
lower extremity Edema
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
lower extremity pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
mental slowing
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
mid upper back pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
migraine
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Acute Pulmonary Embolism
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Anemia
|
86.4%
51/59 • Number of events 57 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
35.6%
21/59 • Number of events 21 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Generalized Rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Hematochezia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Hypogammaglobulinemia
|
1.7%
1/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Intermittent Nosebleeds
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Left Eat Discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Left hip Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Left hip Swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Lower Extremity Bilateral Edema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Oropharyngeal Erythema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Orthostatic Hypertension
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Pain Plantar bilateral Feet
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Right Groin Tenderness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Runny Nose
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Scant Vaginal Bleeding
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Throat Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Upper Extremity Bilateral Edema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Vaginal Thrombus
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
Xerostomia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
bilateral submandibular swelling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
gi blood loss
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
norovirus
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
polyuria
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
vitamin D deficient
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Blood and lymphatic system disorders
vitamin D. Deficiency
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Cardiac disorders
Atrial fibrillation
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Cardiac disorders
Chest pain - cardiac
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Cardiac disorders
Palpitations
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Cardiac disorders
Sinus bradycardia
|
11.9%
7/59 • Number of events 8 • Up to 2 years post transplant.
|
|
Cardiac disorders
Sinus tachycardia
|
30.5%
18/59 • Number of events 18 • Up to 2 years post transplant.
|
|
Cardiac disorders
Wide complex tachycardia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Congenital, familial and genetic disorders
Chest Congestion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Congenital, familial and genetic disorders
blisters bilateral feet
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Ear and labyrinth disorders
Ear pain
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Ear and labyrinth disorders
Tinnitus
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Ear and labyrinth disorders
Vertigo
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Ear and labyrinth disorders
Vestibular disorder
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Ear and labyrinth disorders
ear discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Endocrine disorders
Adrenal insufficiency
|
3.4%
2/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Eye disorders
Blurred vision
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Eye disorders
Eye pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Eye disorders
Vision decreased
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Eye disorders
pale conjunctiva
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Abdominal distension
|
15.3%
9/59 • Number of events 10 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Abdominal pain
|
42.4%
25/59 • Number of events 26 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Bloating
|
11.9%
7/59 • Number of events 7 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Constipation
|
59.3%
35/59 • Number of events 38 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Diarrhea
|
93.2%
55/59 • Number of events 60 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Dry mouth
|
13.6%
8/59 • Number of events 8 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Dyspepsia
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Dysphagia
|
13.6%
8/59 • Number of events 8 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Enterocolitis
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Epigastric discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Epigastric pain
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Esophageal pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Esophagitis
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Fecal incontinence
|
8.5%
5/59 • Number of events 5 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Flatulence
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
GI GVHD
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
GI mucositis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
GI toxicity
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
13.6%
8/59 • Number of events 8 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Hearburn
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Hemorrhoids
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Indigestion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
MOUTH ULCERS
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Mucositis oral
|
54.2%
32/59 • Number of events 32 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Nausea
|
88.1%
52/59 • Number of events 60 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Oral hemorrhage
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Oral pain
|
16.9%
10/59 • Number of events 10 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Rectal pain
|
16.9%
10/59 • Number of events 10 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Rectal ulcer
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Recurrent GI Bleed
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Stomach pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
Vomiting
|
61.0%
36/59 • Number of events 37 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
apthous ulcer
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
gingival bleeding
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
heartburn
|
6.8%
4/59 • Number of events 4 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
hematemesis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
hematochezia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
oral lesion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
Gastrointestinal disorders
tongue lesion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Face only
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
left wrist
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
neck
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
upper extremities
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
2 Detection (oral swab)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
ADV Viremia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Abdominal Bloating
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Abdominal Cramping
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
General disorders
Abdominal Discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Acute GI GVHD
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Acute GVHD skin
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Acute renal insufficiency
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Aphasia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Apthous ulcers ( oral)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Arm Tingling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Foot Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Forearm Macular Rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Hip Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Leg soreness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Lower Extremity Edema
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Lower Extremity Tingling
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Lower extremity Edema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral Upper Extremity tremor
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bilateral hand sensitivity
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bleeding from picc Site
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Blister bottom of left foot
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Bone Pain under Spine
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
C.Diff Colonization positive
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
COV-2 Positive
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Candida Albicans, Few Saccharomyces Cervisiae, Buddign yeast spores
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Catheter pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Chest Discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Chills
|
27.1%
16/59 • Number of events 17 • Up to 2 years post transplant.
|
|
General disorders
Clostridioides Difficile Positive
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Clostridioides Difficile Toxin B Gene by PCR detected
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Clostridium Difficile Infection
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Congestion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Coronavirus HKU1 infection
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Diffuse mucosal bleeding
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Discomfort Left posterior base of tongue
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Double blurred Vision
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Dry Cough
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
E. Coli Bacteremia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Ecchymosis Left Cheek
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Edema Bilateral Lower Extremeties
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Edema Bilateral Lower Extremities
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Edema LE's
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Edema Lower extremeties
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Edema face
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Edema limbs
|
11.9%
7/59 • Number of events 8 • Up to 2 years post transplant.
|
|
General disorders
Edema trunk
|
5.1%
3/59 • Number of events 3 • Up to 2 years post transplant.
|
|
General disorders
Epigastric Discomfort
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Eruthema @ PICC line insertion site
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Erytehmatous Rash Bilateral Forearms
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Erythema Bridge of Nose
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Erythema Right Buccal Mucosa
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Erythematous Rash Chest
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Erythematous Rash Neck
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Facial Edema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Facial Rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Facial pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Fatigue
|
76.3%
45/59 • Number of events 48 • Up to 2 years post transplant.
|
|
General disorders
Fever
|
67.8%
40/59 • Number of events 40 • Up to 2 years post transplant.
|
|
General disorders
Flu like symptoms
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
GVHD skin
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Generalized Body Ache
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Generalized Body Aches
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Generalized Body aches
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Generalized Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Generalized body pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Generalized edema
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Generalized joint pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Generalized pain
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Generalized weakness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Growth of Staph Species Coag Neg
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
HHV6 viremia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Hand pruritis
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Heartburn
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Hemorrhoids
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Hypertrophy Right Buccal Tissue
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Hypothermia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Inflammation around exit site of PICC Line
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Intermittent Nausea
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Intermittent Neuropathy left lower extremity
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Intermittent epigastric pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Intermittent productive cough
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Intermittent right flank pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Itching
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
LLQ abdominal pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Left Arm Numbness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Left Hip Pain (musculoskeletal)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Left Inner Cheek Erythema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Left Shoulder Pain
|
3.4%
2/59 • Number of events 2 • Up to 2 years post transplant.
|
|
General disorders
Left Toe Gout Pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Left Wrist bone pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Left abdominal Discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Left shin Injury
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Leg cramping
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Leg pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Lesion Tip of Tongue
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Light Pseudomonas aeruginosa infection
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Lip Tremor
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Lip ulcer
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Liver GVHD
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Lower Extremity Cramps
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Lower Lip lesion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Lower extremity bilateral pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Maculopapular rash scalp
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Malaise
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Neck Itching
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Neck Rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Neck Stiffness
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Neck edema
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Non Blanchable redness to foot
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Non-cardiac chest pain
|
13.6%
8/59 • Number of events 8 • Up to 2 years post transplant.
|
|
General disorders
Odynophagia
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Onset Facial Rash
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Oral sensitivity
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Orthostatic Hypotension
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Pain
|
18.6%
11/59 • Number of events 14 • Up to 2 years post transplant.
|
|
General disorders
Pain ( ears/nose)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Pain (epigastric)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Pain (penile)
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Pain LE's
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Pain after CVP insertion
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Paresthesia Toes
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Perianal Discomfort
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Perirectal pain
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Petichial Rash Bilateral Lower Extremity
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
|
General disorders
Rare Saccharomyces cervisiae
|
1.7%
1/59 • Number of events 1 • Up to 2 years post transplant.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place